Customizing systemic therapy in patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Customizing systemic therapy in patients with advanced non-small cell lung cancer

Published:2011-06-15 Issue:4 Volume:3 Page:207-218
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Sadowska A. M.¹,Nowé V.²,Janssens A.²,Boeykens E.²,De Backer W. A.²,Germonpré P. R.²

Affiliation:

1. Dept of Respiratory Medicine, University Hospital Antwerp, Wilrijkstraat 10, 2650 Antwerp, Belgium

2. Department of Pulmonary Medicine, Antwerp University Hospital and University of Antwerp, Belgium

Abstract

Lung cancer is the leading cause of cancer deaths worldwide. Standard chemotherapy has been shown to improve quality of life and has a modest influence on overall survival. This modest improvement in survival is partly due to the choice of chemotherapy regimens that have been based on prognostic factors such as age, performance status and comorbidities of the patient. This underlines the importance of developing a more personalized therapy for patients with non-small cell lung cancer. Such an approach may reduce the variation in how individual patients respond to medications by tailoring therapies to their genetic profile. In this review we focus on several aspects of customized therapy, looking not only at patient characteristics but also to tumor histology and specific tumor biomarkers.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834011409000

Reference58 articles.

1. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

2. Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials

3. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

4. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

5. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paeonol Suppresses Proliferation and Motility of Non-Small-Cell Lung Cancer Cells by Disrupting STAT3/NF-κB Signaling;Frontiers in Pharmacology;2020-11-12

2. In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non–small‐cell lung cancer;Journal of Cellular and Molecular Medicine;2019-10-22

3. Detecting EGFR mutations in patients with non-small cell lung cancer;Balkan Journal of Medical Genetics;2018-06-01

4. Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer;Drugs of Today;2018

5. Matrine induction of reactive oxygen species activates p38 leading to caspase-dependent cell apoptosis in non-small cell lung cancer cells;Oncology Reports;2013-09-09